What is the appropriate treatment for Sydenham chorea, including long‑term streptococcal prophylaxis, anti‑inflammatory therapy, and symptomatic control?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Sydenham Chorea

All patients with Sydenham chorea should receive immediate antibiotic treatment at first presentation, followed by long-term secondary antibiotic prophylaxis, with corticosteroids recommended for moderate to severe cases, and symptomatic agents reserved for those requiring additional movement control. 1

Antibiotic Management

Acute Treatment

  • Initiate antibiotics immediately at first presentation, regardless of whether acute streptococcal infection is documented 1
  • This addresses potential ongoing or subclinical Group A streptococcal infection

Long-Term Prophylaxis

  • Follow international or local ARF guidelines for secondary prophylaxis duration 1
  • Benzathine penicillin G is the standard prophylactic agent
  • Antibiotic prophylaxis significantly reduces chorea recurrence rates (odds ratio 0.28 for relapse) 2
  • For patients with recurrent disease, consider more frequent dosing intervals (e.g., every 3 weeks instead of 4 weeks) 3
  • Implement pain reduction strategies for intramuscular injections to improve adherence 1

Critical caveat: Irregular antibiotic prophylaxis is a major risk factor for chorea recurrence 3

Immunotherapy

Corticosteroids (First-Line Immunotherapy)

Corticosteroids are recommended for moderate to severe Sydenham chorea 1

The evidence strongly supports corticosteroid use:

  • Patients receiving ≥1 month of corticosteroids had median chorea duration of 1.2 months versus 2.8 months without treatment (p=0.004) 2
  • Corticosteroids reduce relapse risk substantially (OR 0.32; patients on ≥1 month had OR 0.10 for relapse) 2
  • Prednisolone shows promising results with weight gain as the primary side effect 4

Second-Line Immunotherapy

For patients with inadequate recovery after corticosteroids:

  • Intravenous immunoglobulin (IVIG) should be given 1
  • Plasma exchange is an alternative option 1

The evidence for these modalities is limited to small case series 5, but the 2025 consensus guidelines support their use in refractory cases 1

Symptomatic Treatment

When to Use Symptomatic Agents

Reserve symptomatic medications for:

  • Patients requiring additional movement control beyond immunotherapy
  • Those with severe functional impairment from chorea
  • Bridging therapy while awaiting immunotherapy response

Dopamine Antagonists

  • Haloperidol is the most commonly used dopamine antagonist 4
  • Effective for chorea suppression but does not alter disease course
  • Monitor for extrapyramidal side effects

Antiepileptic Drugs

  • Valproic acid (sodium valproate) is the preferred antiepileptic 4
  • Associated with reduced relapse risk (OR 0.33) 2
  • May have dual benefit: symptomatic control plus disease-modifying effects

Important caveat: Symptomatic drugs alone were associated with higher relapse risk (p=0.045) compared to immunomodulatory therapy 6, reinforcing that they should not be used as monotherapy when immunotherapy is indicated.

Treatment Algorithm by Severity

Mild Cases

  1. Antibiotics (acute + prophylaxis)
  2. Consider observation if minimal functional impairment
  3. Add symptomatic agents only if needed

Moderate to Severe Cases

  1. Antibiotics (acute + prophylaxis)
  2. Corticosteroids (prednisolone) for ≥1 month 1, 2
  3. Add symptomatic agents (valproic acid or haloperidol) if additional control needed
  4. If inadequate response: IVIG or plasma exchange 1

Relapse Cases

  1. Repeat clinical assessment and etiological investigation 1
  2. Restart or intensify antibiotics
  3. Corticosteroid therapy should be considered 1
  4. Evaluate antibiotic prophylaxis adherence and consider more frequent dosing 3

Monitoring and Support

Clinical Monitoring

Screen for and address:

  • Behavioral impairments (anxiety/depression in 77% of cases) 6
  • Mobility limitations
  • Swallowing difficulties
  • Speech impairments
  • Cognitive dysfunction
  • Carditis (present in 81%, often subclinical) 6

Psychosocial Support

  • Provide information and guidance to patients, families, and educators 1
  • Minimize impact on academic and social functioning 1
  • Neuropsychiatric symptoms persist beyond 12 months in 10% of patients 6

Key Pitfalls to Avoid

  1. Do not assume SC is benign and self-limiting - this outdated view leads to undertreatment 6
  2. Do not use symptomatic agents as monotherapy in moderate-severe cases - they increase relapse risk without immunotherapy 6
  3. Do not neglect cardiac evaluation - 81% have carditis, often subclinical 6
  4. Do not discontinue antibiotic prophylaxis prematurely - irregular use is a major relapse risk factor 3
  5. Do not delay immunotherapy in moderate-severe cases - earlier treatment shortens disease duration 2

References

Research

Rare Recurrence of Sydenham Chorea in an Adult: A Case Report.

International medical case reports journal, 2023

Research

Treatment of Sydenham's Chorea: A Review of the Current Evidence.

Tremor and other hyperkinetic movements (New York, N.Y.), 2017

Research

A nationwide study on Sydenham's chorea: Clinical features, treatment and prognostic factors.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.